These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39069844)

  • 1. Efficacy, tolerability, and quality of life evaluation in six patients affected by Gorlin-Goltz syndrome and treated with vismodegib 150 mg/die: a retrospective monocentric cohort analysis.
    Scotti B; Melotti B; Baraldi C; Venturi F; Lambertini M; Dika E
    Ital J Dermatol Venerol; 2024 Aug; 159(4):453-454. PubMed ID: 39069844
    [No Abstract]   [Full Text] [Related]  

  • 2. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.
    Wolfe CM; Green WH; Cognetta AB; Hatfield HK
    Dermatol Surg; 2012 Nov; 38(11):1863-6. PubMed ID: 22805146
    [No Abstract]   [Full Text] [Related]  

  • 3. 9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient.
    Kieny A; Kremer V; Scheidecker S; Lipsker D
    Acta Derm Venereol; 2018 Feb; 98(2):287-288. PubMed ID: 29057423
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
    Tang JY; Mackay-Wiggan JM; Aszterbaum M; Yauch RL; Lindgren J; Chang K; Coppola C; Chanana AM; Marji J; Bickers DR; Epstein EH
    N Engl J Med; 2012 Jun; 366(23):2180-8. PubMed ID: 22670904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Calcium Channel Blockade on Vismodegib-Induced Muscle Cramps.
    Ally MS; Tang JY; Lindgren J; Acosta-Raphael M; Rezaee M; Chanana AM; Epstein EH
    JAMA Dermatol; 2015 Oct; 151(10):1132-4. PubMed ID: 26200175
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Tang JY; Ally MS; Chanana AM; Mackay-Wiggan JM; Aszterbaum M; Lindgren JA; Ulerio G; Rezaee MR; Gildengorin G; Marji J; Clark C; Bickers DR; Epstein EH
    Lancet Oncol; 2016 Dec; 17(12):1720-1731. PubMed ID: 27838224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome.
    Yang X; Dinehart SM
    JAMA Dermatol; 2016 Feb; 152(2):223-4. PubMed ID: 26509945
    [No Abstract]   [Full Text] [Related]  

  • 8. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome.
    Chang AL; Atwood SX; Tartar DM; Oro AE
    JAMA Dermatol; 2013 May; 149(5):639-41. PubMed ID: 23677114
    [No Abstract]   [Full Text] [Related]  

  • 9. Trichodysplasia spinulosa in gorlin syndrome treated with vismodegib.
    Lopez-Lerma I; Mollet J; Garcia-Patos V
    JAMA Dermatol; 2015 Apr; 151(4):458-9. PubMed ID: 25471402
    [No Abstract]   [Full Text] [Related]  

  • 10. Comment on basal cell carcinoma rebound after cessation of vismodegib in an individual with basal cell nevus syndrome.
    Ally MS; Wysong A; Tang JY; Aasi S
    Dermatol Surg; 2013 Sep; 39(9):1413-4. PubMed ID: 23682843
    [No Abstract]   [Full Text] [Related]  

  • 11. Trichodysplasia spinulosa in gorlin syndrome treated with vismodegib-reply.
    Richey JD; Katona T; Travers JB
    JAMA Dermatol; 2015 Apr; 151(4):459. PubMed ID: 25471598
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of trichodysplasia spinulosa: case report of a patient with Gorlin syndrome treated with vismodegib.
    Richey JD; Graham TA; Katona T; Travers JB
    JAMA Dermatol; 2014 Sep; 150(9):1016-8. PubMed ID: 25054782
    [No Abstract]   [Full Text] [Related]  

  • 13. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 14. Analysis of basal cell carcinomas' histological subtypes and relative response to vismodegib in six patients diagnosed with Gorlin-Goltz syndrome: A retrospective study.
    Scotti B; Melotti B; Baraldi C; Comito F; Venturi F; Lambertini M; Dika E
    J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):e339-e341. PubMed ID: 37909360
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral smoothened inhibitors for Gorlin syndrome: A clinical review.
    Baczynski A; Cahn B; Worley B; Haber R; Alam M
    J Am Acad Dermatol; 2024 Oct; 91(4):706-711. PubMed ID: 38950707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vismodegib in real-life clinical settings: A multicenter, longitudinal cohort providing long-term data on efficacy and safety.
    Apalla Z; Spyridis I; Kyrgidis A; Lazaridou E; Kyriakou A; Fotiadou C; Pikou O; Sotiriou E; Vakirlis E; Papageorgiou C; Delli F; Moutsoudis A; Manoli SM; Ioannides D; Lallas A
    J Am Acad Dermatol; 2021 Dec; 85(6):1589-1592. PubMed ID: 33253837
    [No Abstract]   [Full Text] [Related]  

  • 17. Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study.
    Bossi P; Peris K; Calzavara-Pinton P; Queirolo P; Alfieri S; Palla M; Rossi MT; Spagnolo F; Tambone S; Astolfi C; Ascierto PA
    Future Oncol; 2020 Jun; 16(16):1091-1100. PubMed ID: 32374193
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
    Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
    Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.